This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prevention of TB in HIV-infected persons

Authoring team

Infection with HIV is the strongest known risk-factor for the development of tuberculosis. Possible means of intervention include:

  • case-finding and treatment
  • preventive therapy
  • environmental measures

Preventive therapy with isoniazid is now recommended internationally. However, it is not clear that current guidelines are adhered to in developed countries, and they have received limited attention in resource-poor countries.

The optimal drug regimen and duration of therapy have not been clearly established, and the possible emergence of drug resistance is a concern. Active tuberculosis must be excluded before and during the course of preventive therapy, so as to avoid inadequate therapy and the rapid dissemination of drug-resistant strains.

Notes:

  • BCG is contraindicated in symptomatic HIV-positive individuals (1). In countries such as the UK where the risk of TB is low, it is recommended that BCG is also withheld from all those known to be or suspected to be HIV positive, regardless of clinical status. Where vaccination is indicated, for example infants born to HIV-positive mothers, this can be administered after two appropriately timed negative postnatal PCR tests for HIV infection.

Reference:

  1. Immunisation Against Infectious Disease - "The Green Book".Chapter 32 tuberculosis (January 2016).

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.